<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354276</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000492755</org_study_id>
    <secondary_id>VION-CLI-043</secondary_id>
    <secondary_id>EUDRACT-2006-001853-89</secondary_id>
    <nct_id>NCT00354276</nct_id>
    <nct_alias>NCT00389623</nct_alias>
  </id_info>
  <brief_title>VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving VNP40101M followed by cytarabine may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well VNP40101M followed by cytarabine works in&#xD;
      treating older patients with acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the complete response rate in older patients with poor-risk, de novo acute&#xD;
           myeloid leukemia treated with VNP40101M as induction therapy followed by cytarabine as&#xD;
           consolidation therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the probability of overall survival, leukemia-free survival, and&#xD;
           progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive VNP40101M IV over 60 minutes on day 1 (course 1).&#xD;
           Patients without evidence of disease progression who have responding but residual&#xD;
           disease receive a second course of VNP40101M once between days 35-60. Patients achieving&#xD;
           complete response or partial response after induction therapy proceed to consolidation&#xD;
           therapy.&#xD;
&#xD;
        -  Consolidation therapy: Beginning between days 45-90, patients receive cytarabine IV&#xD;
           continuously over 5 days (course 1). Patients may receive a second course of cytarabine&#xD;
           at the discretion of the investigator.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 36 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 85 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laromustine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed de novo acute myeloid leukemia (AML)&#xD;
&#xD;
               -  No acute promyelocytic leukemia [t(15;17)]&#xD;
&#xD;
               -  No favorable cytogenetics, including t(15;17), t(8;21), or inv 16&#xD;
&#xD;
               -  No secondary AML, defined as having a history of an antecedent hematologic&#xD;
                  disorder (myelodysplastic syndromes [MDS] or myeloproliferative disease), or&#xD;
                  history of prior chemotherapy or radiation for a disease other than AML&#xD;
&#xD;
          -  Must have ≥ 1 of the following poor-risk features:&#xD;
&#xD;
               -  Any of the following unfavorable cytogenetics:&#xD;
&#xD;
                    -  Del (5q)/-5q&#xD;
&#xD;
                    -  -7/del(7q)&#xD;
&#xD;
                    -  Abnormal 3q, 9q, 11q, 20q, 21q, or 17p&#xD;
&#xD;
                    -  t(6;9)&#xD;
&#xD;
                    -  t(9;22)&#xD;
&#xD;
                    -  Trisomy 8&#xD;
&#xD;
                    -  Complex karyotypes (≥ 3 unrelated abnormalities)&#xD;
&#xD;
               -  At least 70 years of age&#xD;
&#xD;
               -  ECOG performance status (PS) of 2&#xD;
&#xD;
               -  Cardiac dysfunction* that would limit the use of anthracycline therapy, as&#xD;
                  defined by any of the following:&#xD;
&#xD;
                    -  Ejection fraction ≤ 50%&#xD;
&#xD;
                    -  History of significant coronary artery disease, defined as ≥ 1 vessel&#xD;
                       stenosis requiring medical treatment, stent placement, or surgical bypass&#xD;
                       graft&#xD;
&#xD;
                    -  History of congestive heart failure or myocardial infarction&#xD;
&#xD;
                    -  Significant arrhythmia, including any of the following:&#xD;
&#xD;
                         -  Atrial flutter (excluding atrial fibrillation)&#xD;
&#xD;
                         -  Sick sinus syndrome&#xD;
&#xD;
                         -  Ventricular arrhythmia&#xD;
&#xD;
                    -  Heart valve disease&#xD;
&#xD;
                         -  Mitral valve prolapse allowed&#xD;
&#xD;
                    -  Other heart disease, at the discretion of the principal investigator&#xD;
&#xD;
               -  Pulmonary dysfunction not related to AML, defined by 1 of the following:&#xD;
&#xD;
                    -  DLCO and/or FEV_1 &lt; 80% and ≥ 50% normal range&#xD;
&#xD;
                    -  Dyspnea on slight activity or at rest&#xD;
&#xD;
                    -  Requires oxygen&#xD;
&#xD;
               -  Hepatic dysfunction related to chronic hepatitis or liver cirrhosis&#xD;
&#xD;
               -  Other organ dysfunction or comorbidity that precludes standard cytotoxic&#xD;
                  induction treatment (e.g., &quot;3+7&quot;), at the discretion of the principal&#xD;
                  investigator NOTE: *Patients with a history of heart disease as defined above&#xD;
                  must be on appropriate medication and have their disease under control&#xD;
&#xD;
          -  No known CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  AST and ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No active, uncontrolled infection&#xD;
&#xD;
               -  Patients with an infection who are under active treatment with antibiotics and&#xD;
                  whose infections are controlled are eligible&#xD;
&#xD;
               -  Chronic hepatitis allowed&#xD;
&#xD;
          -  No clinical evidence of ongoing second malignancy unrelated to AML or MDS&#xD;
&#xD;
          -  No evidence of left bundle branch block on screening ECG&#xD;
&#xD;
          -  No obligate use of cardiac pacemaker or atrial fibrillation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 24 hours since prior metronidazole&#xD;
&#xD;
          -  No prior low-dose, single-agent, cytotoxic chemotherapy (e.g., cytarabine, decitabine,&#xD;
             or azacitidine)&#xD;
&#xD;
          -  No concurrent disulfiram&#xD;
&#xD;
          -  No other concurrent standard or investigational therapy for AML except for the&#xD;
             following:&#xD;
&#xD;
               -  Concurrent hydroxyurea to control rising white blood cell counts&#xD;
&#xD;
                    -  Dosage must be 4-6 grams daily for up to 4 days&#xD;
&#xD;
               -  Concurrent leukapheresis to control blast cell counts&#xD;
&#xD;
                    -  Must be completed within the first 5 days of study therapy&#xD;
&#xD;
                    -  No more than 2 procedures per day or 4 procedures total&#xD;
&#xD;
               -  Investigational supportive care agents (e.g., antimicrobials or antifungal&#xD;
                  agents), at the discretion of the protocol sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonny L. Johnson, RN, MSN</last_name>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

